Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Arda Celen"'
Autor:
Stephanie R. Jackson Cullison, Arda Celen, Nicole A. Doudican, John A. Carucci, Mary L. Stevenson
Publikováno v:
COVID, Vol 3, Iss 2, Pp 144-150 (2023)
Many surgical practices closed at the onset of the COVID-19 pandemic. We implemented operational changes to safely continue treating patients with cutaneous tumors during the pandemic. This study seeks to evaluate the impact of pandemic-based operati
Externí odkaz:
https://doaj.org/article/1269d621136b42e5ae3976399c78beb5
Autor:
Nicholas Gulati, Arda Celen, Paul Johannet, Janice M. Mehnert, Jeffrey Weber, Michelle Krogsgaard, Iman Osman, Judy Zhong
Publikováno v:
Cancer Medicine, Vol 10, Iss 21, Pp 7457-7465 (2021)
Abstract Background Immune‐related adverse events (irAEs) are common, clinically significant autoinflammatory toxicities observed with immune checkpoint inhibitors (ICI). Preexisting immune‐mediated inflammatory disease (pre‐IMID) is considered
Externí odkaz:
https://doaj.org/article/513209216e8d4e83b5f306ae3cb763e5
Publikováno v:
Journal of Drugs in Dermatology. 22:210-216
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88b6ab7ca694ee56c768fe526a88bcae
https://doi.org/10.36849/jdd.6926
https://doi.org/10.36849/jdd.6926
Autor:
Michelle Krogsgaard, Iman Osman, Janice M. Mehnert, Jeffrey S. Weber, Nicholas Gulati, Arda Celen, Judy Zhong, Paul Johannet
Publikováno v:
Cancer Medicine, Vol 10, Iss 21, Pp 7457-7465 (2021)
Cancer Medicine
Cancer Medicine
Background Immune‐related adverse events (irAEs) are common, clinically significant autoinflammatory toxicities observed with immune checkpoint inhibitors (ICI). Preexisting immune‐mediated inflammatory disease (pre‐IMID) is considered a relati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2359b1da5aabf7b7fa1a072d538be88c
https://doaj.org/article/513209216e8d4e83b5f306ae3cb763e5
https://doaj.org/article/513209216e8d4e83b5f306ae3cb763e5
Autor:
Amelia Sawyers, Arda Celen, Michelle Krogsgaard, Iman Osman, Jeffrey S. Weber, Min Jae Kim, Nicholas Gulati, Janice M. Mehnert, Judy Zhong, Paul Johannet
Publikováno v:
Journal of Clinical Oncology. 39:e21586-e21586
e21586 Background: Immune checkpoint inhibition (ICI) improves progression-free (PFS) and overall survival (OS) for patients with metastatic melanoma (MM), but induces immune-related adverse events (irAEs). Pre-existing autoimmune disease (pre-AI) is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a05a4b8b266c60aab25a079a13a2a2cf
https://doi.org/10.1200/jco.2021.39.15_suppl.e21586
https://doi.org/10.1200/jco.2021.39.15_suppl.e21586